J Hepatol: Efficacy update of Atezolizumab combined with bevacizumab vs sorafenib in the treatment of unresectable hepatocellular carcinoma: IMbrave150

IMbrave150 is a phase III open-label clinical study that mainly evaluates the efficacy and safety of PD-L1 inhibitor atezolizumab combined with bevacizumab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma ( HCC )
.

In a preliminary analysis after a median follow-up of 8.

IMbrave150 is a phase III open-label clinical study that mainly evaluates the efficacy and safety of PD-L1 inhibitor atezolizumab combined with bevacizumab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma ( HCC )

The study assigned patients 2:1 to atezolizumab+bevacizumab and sorafenib treatment
.

The dose of atezolizumab was 1200 mg/day/d1, bevacizumab was 15 mg/kg/day/d1, intravenously q3W, and the dose of sorafenib was 400 mg bid po

The study assigned patients 2:1 to atezolizumab+bevacizumab and sorafenib treatment

From March 15, 2018 to January 30, 2019, 501 patients (intent-to-treat population) were randomly assigned to atezolizumab + bevacizumab (n=336) or sorafenib (n=165)

As of 2020 Nian 8 months 31 days, after a median 15.

The median OS of the two groups of patients were 19.

os

os

The median PFS of the two groups of patients were 6.
9 months (95% CI 5.
7-8.
6) and 4.
3 months (95% CI 4.
0-5.
6), respectively (HR, 0.
65; 95% CI 0.
53-0.
81; p <0.
001)
.

The median PFS of the two groups of patients were 6.
9 months (95% CI 5.
7-8.
6) and 4.
3 months (95% CI 4.
0-5.
6), respectively (HR, 0.
65; 95% CI 0.
53-0.
81; p <0.
001)
.

The median PFS of the two groups of patients were 6.

                    PFS

PFS

The ORRs of the two groups were 30% (95% CI 25-35) and 11% (95% CI 7-17)
.

The complete remission rate was 8% and less than 1%, respectively

The ORRs of the two groups were 30% (95% CI 25-35) and 11% (95% CI 7-17)

                 Efficacy evaluation

Efficacy evaluation

Treatment-related grade 3/4 adverse events occurred in 143 (43%) of 329 patients in the atezolizumab + bevacizumab group and 72 (46%) of 156 patients in the sorafenib group
.

Treatment-related grade 5 events occurred in 6 (2%) and 1 (<1%) patients, respectively

Treatment-related grade 3/4 adverse events occurred in 143 (43%) of 329 patients in the atezolizumab + bevacizumab group and 72 (46%) of 156 patients in the sorafenib group
.
Treatment-related grade 5 events occurred in 6 (2%) and 1 (<1%) patients, respectively
.

In summary, the IMbrave150 study with increased follow-up time confirmed that atezolizumab + bevacizumab still maintains the prognostic efficacy of sorafenib in improving the prognosis of patients with unresectable hepatocellular carcinoma
.

In summary, the IMbrave150 study
with increased follow-up time confirmed that atezolizumab + bevacizumab still maintains the prognostic efficacy of sorafenib in improving the prognosis of patients with unresectable hepatocellular carcinoma .
The IMbrave150 study with increased follow-up time confirmed that atezolizumab + bevacizumab still maintains the prognostic effect of improving the prognosis of patients with unresectable hepatocellular carcinoma compared with sorafenib
.
The IMbrave150 study with increased follow-up time confirmed that atezolizumab + bevacizumab still maintains the prognostic effect of improving the prognosis of patients with unresectable hepatocellular carcinoma compared with sorafenib
.

Original source:

Original source:

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L , Zhu AX, Finn RS.
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs.
sorafenib for unresectable hepatocellular carcinoma.
J Hepatol.
2021 Dec 10:S0168-8278(21)02241-8.
doi: 10.
1016/j.
jhep .
2021.
11.
030.
Epub ahead of print.
PMID: 34902530.

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L , Zhu AX, Finn RS.
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs.
sorafenib for unresectable hepatocellular carcinoma.
J Hepatol.
2021 Dec 10:S0168-8278(21)02241-8.
doi: 10.
1016/j.
jhep .
2021.
11.
030.
Epub ahead of print.
PMID: 34902530.
Leave a message here